Market Overview:

According to IMARC Group's latest research publication, "Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The global gene therapy market size was valued at USD 6.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 19.3 Billion by 2034, exhibiting a CAGR of 12.27% from 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How Gene Therapy Is Transforming the Future of Medicine

• CRISPR-Cas9 technology is revolutionizing gene editing precision, enabling targeted correction of defective sequences responsible for conditions like sickle cell anemia and cystic fibrosis, reducing trial failure rates significantly.

• The U.S. FDA has fast-tracked approvals for rare disease gene therapies, with Orchard Therapeutics launching Lenmeldy, the first approved gene therapy for early-onset metachromatic leukodystrophy (MLD), priced at USD 4.25 million per treatment.

• The Gene Therapy Innovation Fund (GTIF) allocates USD 6.1 Million annually to support academic researchers developing novel viral vector-based therapies, reviewed and disbursed twice a year.

• CAR-T cell therapies, engineered using antigen-based gene editing, are achieving breakthrough results in treating aggressive blood cancers and lymphomas that were previously resistant to conventional treatment.

• Adeno-associated virus (AAV) vectors, preferred for their low immunogenicity and high safety profile, now account for the majority of active gene therapy clinical trials globally, expanding the treatable disease spectrum.

Download a sample PDF of this report: https://www.imarcgroup.com/gene-therapy-market/requestsample

Key Trends in the Gene Therapy Market

• Advancements in Viral Vector Technology: Viral vectors, particularly AAVs and lentiviruses, continue to evolve with higher payload capacities and precision targeting. Companies like MERCK KGaA are developing platforms such as the Virus Express 293 AAV Production Platform, while Catalent Inc. has launched the UpTempo Virtuoso platform for advanced AAV manufacturing, expanding access to therapies for complex genetic disorders.

• Surge in R&D Investment and Funding: Pharmaceutical giants and biotech firms are pouring resources into gene therapy pipelines. Government-backed grant programs, including the GTIF's USD 6.1 Million annual allocation, are enabling academic research to transition into GMP-grade clinical development, directly supporting the commercialization of next-generation therapies.

• Rising Prevalence of Genetic and Rare Diseases: Genetic disorders such as spinal muscular atrophy (SMA), which affects approximately 1 in every 10,000 people globally, and hemophilia are fueling demand for curative interventions. Gene therapy's ability to correct the root genetic cause, often with a single administration, makes it a transformative solution for underserved patient populations.

• Regulatory Streamlining and Government Support: Many governmental bodies are simplifying approval pathways for rare disease therapies. The FDA's Rare Pediatric Disease Priority Review and Breakthrough Therapy designations have accelerated market entry for novel gene therapies, boosting investor and industry confidence.

• Personalized and Antigen-Based Therapy Expansion: Personalized medicine is leveraging tumor-associated antigens to develop patient-specific cancer vaccines and CAR-T treatments. Research efforts are focused on discovering novel antigens and optimizing delivery mechanisms to improve efficacy and minimize side effects in oncology applications.

Growth Factors in the Gene Therapy Market

• Growing Incidence of Cancer and Chronic Disease: The U.S. Centers for Disease Control and Prevention reported 1,777,566 new cancer cases in 2021 alone. As chronic diseases with genetic components continue to rise, demand for gene-level interventions that address root causes rather than symptoms is witnessing strong growth momentum.

• Technological Breakthroughs in Delivery Systems: Non-viral delivery techniques including electroporation, lipofection, and plasmid vectors are expanding therapy access by reducing manufacturing complexity. These innovations are enhancing delivery efficiency and lowering patient risk profiles across a wider range of applications.

• Strategic Collaborations and M&A Activity: Pharmaceutical corporations are acquiring gene therapy startups and building dedicated internal divisions to accelerate research pipelines. Academic-industry partnerships are also driving faster commercialization of viral vector-based therapies, reinforcing competitive positioning across key markets.

• Ex Vivo Therapy Breakthroughs: Lentiviruses and retroviruses are extensively applied in ex vivo therapies like CAR-T cell treatments for cancer. These approaches, which modify patient cells outside the body before reinfusion, are gaining strong clinical validation and commercial traction globally.

• Expansion of AAV-Based Therapies: Viral vectors currently account for 55.5% of the global gene therapy market share, with AAV leading due to its superior safety profile and stable gene expression. Increased regulatory approvals and R&D funding are accelerating AAV adoption across oncology, neurology, and rare disease segments.

Gene therapy market size forecast 2026 driven by advancements in genetic technologies, rising demand for targeted treatments, and increasing investment in biotechnology research.

Leading Companies Operating in the Global Gene Therapy Industry:

• Orchard Therapeutics
• MERCK KGaA
• Catalent Inc.
• Novartis AG
• Gilead Sciences (Kite Pharma)
• Bristol-Myers Squibb
• Spark Therapeutics
• bluebird bio Inc.
• Sarepta Therapeutics
• UniQure N.V.

Gene Therapy Market Report Segmentation:

Breakup By Gene Type:

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide Gene
• Deficiency
• Growth Factors
• Receptors
• Others

Antigens account for a significant segment share due to their central role in CAR-T therapies and cancer vaccine development targeting malignant tumor cells.

Breakup By Vector Type:

• Viral Vector (Adenoviruses, Lentiviruses, Retroviruses, Adeno-Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Others)
• Non-Viral Techniques  Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Others)

Viral vector dominates the market with 55.5% share, driven by superior transduction efficiency, stable gene expression, and expanding regulatory approvals for AAV-based therapies.

Breakup By Delivery Method:

• In Vivo
• Ex Vivo

Breakup By Application:

• Oncological Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Rare Diseases
• Others

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position with over 56% market share, attributed to advanced healthcare infrastructure, strong biotech ecosystems, and supportive FDA regulatory pathways for gene-based therapies.

Recent News and Developments in the Gene Therapy Market

• April 2024: Orchard Therapeutics announced U.S. launch plans for Lenmeldy (atidarsagene autotemcel), the first FDA-approved gene therapy for early-onset metachromatic leukodystrophy (MLD), with a one-time treatment cost of USD 4.25 million and rollout across five specialized treatment centers.

• September 2024: Catalent Inc. expanded its UpTempo Virtuoso AAV manufacturing platform to support increased demand from biotech partners seeking scalable GMP-grade viral vector production capacity.

• February 2025: MERCK KGaA advanced its Virus Express 293 AAV Production Platform capabilities, enabling full-service viral vector manufacturing for a broader client base pursuing rare disease gene therapy programs.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (D) +91 120 433 0800

United States: +1-631-791-1145